Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 13/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1680670 | 0.86 | KDM4E (0.59) | CYP19A1CYP11B1CYP11B2FFAR1KDM4E | |
| SCHEMBL30689371 | 0.86 | KDM4E (0.59) | CYP19A1CYP11B1CYP11B2FFAR1KDM4E | |
| SCHEMBL2246114 | 0.86 | FFAR1 (0.49) | CYP19A1CYP11B1CYP11B2FFAR1KDM4E | |
| SCHEMBL12356711 | 0.83 | ALDH1A1 (0.50) | KDM4EALDH1A1SMN1; SMN2MAOBPARP10 | |
| SCHEMBL3626120 | 0.82 | MAOB (0.54) | CYP19A1CYP11B1CYP11B2FFAR1KDM4E | |
| SCHEMBL13248358 | 0.80 | ALOX5AP (0.53) | CYP19A1CYP11B1CYP11B2FFAR1KDM4E | |
| SCHEMBL9924105 | 0.79 | FFAR1 (0.46) | CYP19A1CYP11B1CYP11B2FFAR1KDM4E | |
| SCHEMBL16638704 | 0.79 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2MAOBPARP10 | |
| SCHEMBL2795215 | 0.78 | CYP11B1 (0.43) | CYP19A1CYP11B1CYP11B2FFAR1KDM4E | |
| SCHEMBL14009817 | 0.77 | ALDH1A1 (0.42) | FFAR1KDM4EALDH1A1SMN1; SMN2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2546232-A1 | Diphenyl Substituted Alkanes | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2010-07-29 | — | — | US | disclosed |
| EP-2170065-A1 | DIPHENYL SUBSTITUTED ALKANES | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008156721-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | ALOX5, ALOX15, ALOX15B | CYP19A1 835/4885CYP11B1 237/4885CYP11B2 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.